Related Experiment Video

Updated: Jun 27, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide

Begoña López1, Arantxa González, Nerea Hermida

  • 1Division of Cardiovascular Sciences, Center of Applied Medical Research, University of Navarra, Pamplona, Spain.

Kidney International. Supplement
|November 27, 2008
PubMed

Insights

Myocardial fibrosis is common in chronic kidney disease (CKD) and hypertension, contributing to diastolic heart failure. Torasemide may reduce cardiac fibrosis and improve heart function in CKD patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Pathology

Background:

  • Interstitial and perivascular fibrosis is consistently observed in heart biopsies of patients with chronic kidney disease (CKD) and hypertension, particularly those with left ventricular hypertrophy.
  • This fibrosis results from an imbalance between excessive collagen synthesis and inadequate collagen degradation, influenced by factors related to hypertension and declining renal function.
  • Myocardial fibrosis is implicated as a key factor in diastolic dysfunction, a common issue in patients with CKD and hypertension.

Purpose of the Study:

  • To investigate the role of myocardial fibrosis in diastolic heart failure among patients with CKD and hypertension.
  • To explore the potential cardioprotective benefits of therapeutic strategies targeting cardiac fibrosis in this patient population.

Main Methods:

  • Analysis of heart biopsies and necropsy studies in patients with CKD and hypertension.
  • Review of recent data on the effects of the loop diuretic torasemide on myocardial fibrosis and cardiac function.

Main Results:

  • Torasemide has been suggested to reduce myocardial fibrosis.
  • Torasemide may ameliorate cardiac function in patients with chronic heart failure.

Conclusions:

  • Therapeutic strategies aimed at reducing cardiac fibrosis could offer significant cardioprotection for patients with CKD.
  • Torasemide demonstrates potential in mitigating myocardial fibrosis and improving cardiac function through mechanisms beyond its diuretic and hemodynamic effects.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...